Copertina

Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Stefano Cordella, Davide Giusti, Eleonora De Bellis, Michelina Dargenio, Federica Creti’, Davide Lazzarotto, Chiara Cattaneo, Nicola Stefano Fracchiolla, Matteo Piccini, Fabio Forghieri, Livio Pagano, Anna Candoni
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
di: Dian Jin, et al.
Pubblicazione: (2024)

Defining a role for venetoclax and hypomethylating agent therapy in younger adults with acute myeloid leukemia
di: Brandon J. Aubrey, et al.
Pubblicazione: (2026)

Changing acute myeloid leukemia into a chronic disease with long‐term venetoclax
di: Panagiotis Tsarouhas, et al.
Pubblicazione: (2024)

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
di: Sylvain Garciaz, et al.
Pubblicazione: (2024)

The heart of VIALE‐A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia
di: Shyam A. Patel
Pubblicazione: (2024)

Successful venetoclax and azacitidine treatment in pediatric acute myeloid leukemia associated with familial platelet disorder
di: Rikako Tsukamoto, et al.
Pubblicazione: (2025)

Inflammatory signaling in the pathogenesis of acute myeloid leukemia
di: Artemis Margrith Baumann, et al.
Pubblicazione: (2025)

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
di: Isla M. Johnson, et al.
Pubblicazione: (2024)

Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study
di: Pilar Lloret‐Madrid, et al.
Pubblicazione: (2025)

A case of relapsed acute myeloid leukemia mimicking acute otomastoiditis
di: Ivan Negara, et al.
Pubblicazione: (2024)

Leukemia cutis as the first manifestation of acute myeloid leukemia
di: Florian Winkler, et al.
Pubblicazione: (2026)

Concurrent hyperdiploid acute myeloid leukemia and trisomy 12+ chronic lymphocytic leukemia
di: Tulasi Geevar, et al.
Pubblicazione: (2024)

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia
di: Sudhir Manda, et al.
Pubblicazione: (2024)

Emergence of clonal evolution with Philadelphia chromosome in acute myeloid leukemia after hypomethylation agents and BCL2 inhibitor treatment
di: Shih‐Yu Kao, et al.
Pubblicazione: (2024)

Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia
di: Céline Row, et al.
Pubblicazione: (2024)

Glucose‐6‐phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine
di: Shira Buchrits, et al.
Pubblicazione: (2026)

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study
di: Jan Philipp Bewersdorf, et al.
Pubblicazione: (2024)

Acute myocardial infarction in an untreated patient with acute myeloid leukemia
di: Doreen Kamoga, et al.
Pubblicazione: (2024)

Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia
di: Amber Gibson, et al.
Pubblicazione: (2024)

Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE‐A
di: Naseema Gangat, et al.
Pubblicazione: (2024)

Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study
di: André Baruchel, et al.
Pubblicazione: (2025)

Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy
di: Guangyang Weng, et al.
Pubblicazione: (2024)

Mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia
di: J. Maes, et al.
Pubblicazione: (2024)

PIEZO1 is essential for the survival and proliferation of acute myeloid leukemia cells
di: Delphine Lebon, et al.
Pubblicazione: (2024)

Impact of secondary‐type mutations in acute myeloid leukemia with CEBPA mutation
di: Davidson Zhao, et al.
Pubblicazione: (2024)

Nanomaterials for acute myeloid leukemia therapy: Current progress and future perspectives
di: Jiarui Zhao, et al.
Pubblicazione: (2025)

Contemporary outcomes of octa‐nonagenarians with newly diagnosed acute myeloid leukemia
di: Jayastu Senapati, et al.
Pubblicazione: (2025)

Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56‐positive acute leukemias
di: Hanan Hamdan, et al.
Pubblicazione: (2024)

A venetoclax‐cytarabine‐based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia
di: Xiao‐Hua Luo, et al.
Pubblicazione: (2026)

Neuroinflammatory changes in acute myeloid leukemia: Evidence for blood–brain barrier disruption and glial activation
di: Marta Febo, et al.
Pubblicazione: (2026)

Age‐associated myeloid malignancies – the role of STAT3 and STAT5 in myelodysplastic syndrome and acute myeloid leukemia
di: Eirini Sofia Fasouli, et al.
Pubblicazione: (2024)

Methylsulfonylmethane induces caspase‐dependent apoptosis in acute myeloid leukemia cell lines
di: Yalda Hekmatshoar, et al.
Pubblicazione: (2024)

FLT3‐ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia
di: María Turos‐Cabal, et al.
Pubblicazione: (2024)

Solamargine induces acute myeloid leukemia differentiation through TLR8 activation
di: Qiaoyan Han, et al.
Pubblicazione: (2025)

Classification of acute myeloid leukemia based on multi‐omics and prognosis prediction value
di: Yang Song, et al.
Pubblicazione: (2025)

Prognostic impact of extramedullary disease in acute myeloid leukemia: A meta‐analysis
di: Yufan Lin, et al.
Pubblicazione: (2025)

Upregulation of ALDH1 as an adaptive epigenetic response to anthracyclines in acute myeloid leukemia
di: Francesco Leonetti, et al.
Pubblicazione: (2025)

Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia
di: Meihong Chai, et al.
Pubblicazione: (2026)

Unraveling genotype–phenotype associations and predictive modeling of outcome in acute myeloid leukemia
di: Artuur Couckuyt, et al.
Pubblicazione: (2025)

28‐color single tube for flow cytometric assessment of myeloid maturation, myeloid neoplasia, and acute myeloid leukemia minimal/measurable residual disease
di: Qi Gao, et al.
Pubblicazione: (2025)